GOSS Gossamer Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GOSS

Price (delayed)

$0.74

Market cap

$166.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$343.98M

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an ...

Highlights
GOSS's EPS has soared by 56% year-on-year and by 33% since the previous quarter
Gossamer Bio's net income has increased by 22% YoY and by 4.1% from the previous quarter
The quick ratio is down by 26% since the previous quarter but it is up by 11% year-on-year
GOSS's equity is down by 40% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.gossamerbio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of GOSS
Market
Shares outstanding
225.58M
Market cap
$166.93M
Enterprise value
$343.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.66
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$166.31M
EBITDA
-$161.92M
Free cash flow
-$159.16M
Per share
EPS
-$1.18
Free cash flow per share
-$1.04
Book value per share
$0.28
Revenue per share
$0
TBVPS
$2.04
Balance sheet
Total assets
$311.92M
Total liabilities
$249.15M
Debt
$209.16M
Equity
$62.77M
Working capital
$254.92M
Liquidity
Debt to equity
3.33
Current ratio
5.94
Quick ratio
5.74
Net debt/EBITDA
-1.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-67.8%
Return on equity
-944.8%
Return on invested capital
-43.6%
Return on capital employed
-63.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GOSS stock price

How has the Gossamer Bio stock price performed over time
Intraday
-3.9%
1 week
10.45%
1 month
-33.33%
1 year
-44.78%
YTD
-18.9%
QTD
-37.29%

Financial performance

How have Gossamer Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$183.76M
Net income
-$179.82M
Gross margin
N/A
Net margin
N/A
Gossamer Bio's net income has increased by 22% YoY and by 4.1% from the previous quarter
Gossamer Bio's operating income has increased by 16% YoY and by 2.8% QoQ

Growth

What is Gossamer Bio's growth rate over time

Valuation

What is Gossamer Bio stock price valuation
P/E
N/A
P/B
2.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GOSS's EPS has soared by 56% year-on-year and by 33% since the previous quarter
The P/B is 58% less than the 5-year quarterly average of 6.3
GOSS's equity is down by 40% QoQ

Efficiency

How efficient is Gossamer Bio business performance
The company's return on equity has surged by 68% QoQ and by 15% YoY
Gossamer Bio's ROIC has increased by 32% YoY and by 11% from the previous quarter
GOSS's ROA is up by 16% year-on-year and by 8% since the previous quarter

Dividends

What is GOSS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GOSS.

Financial health

How did Gossamer Bio financials performed over time
GOSS's total assets is 25% higher than its total liabilities
The current ratio has contracted by 26% from the previous quarter but it has grown by 12% YoY
The quick ratio is down by 26% since the previous quarter but it is up by 11% year-on-year
The company's debt to equity has shrunk by 82% YoY but it has surged by 64% QoQ
GOSS's equity is down by 40% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.